

**FOR IMMEDIATE RELEASE**

Contact: Colleen Hittle, President & CEO

9001 Wesleyan Road, Suite 200

Indianapolis, Indiana 46268

Phone 317.569.9500 x 102

Fax 317.569.9520

Cell 317.201.8711

[chittle@ansongroup.com](mailto:chittle@ansongroup.com)

[www.ansongroup.com](http://www.ansongroup.com)

**Indiana Biodefense Consortium Formed**

(Indianapolis, IN) The Indiana Biodefense Consortium, LLC (IBC) has been formed to address the threat of bioterrorism by developing less expensive drugs and gaining quick regulatory approval for them.

The IBC's goal is to meet the federal government's need to speed the development, approval, and deployment of vaccines and drugs that would treat the effects of exposure to chemical, biological, radiological, or nuclear materials.

The IBC will be submitting proposals in response to Requests for Proposals (RFPs) by the Department of Health and Human Services and the Department of Defense. The RFPs express the federal government's unmet need for a quicker and more flexible medical countermeasures development process.

Joerg Shreiber, Ph.D., Chief Executive Officer of the IBC, stated, "It's difficult to imagine that a single entity alone can deliver the range of expertise, processes and agile vaccine or drug production capacity required. However, we are convinced that Indiana, with its long history of excellence in drug development, depth of workforce talent, and leadership in academia, life sciences, advanced manufacturing and logistics, is uniquely positioned to create a consortium that can address the government's requests and meet the challenge."

Anson President and CEO Colleen Hittle, RAC, said, "The Anson Group is proud to be a founding member of the Indiana Biodefense Consortium. Indiana has a vast set of resources that can support innovative life science projects like those envisioned by this initiative."

Other members of the IBC include several of Indiana's leading colleges, universities, medical schools, and life science companies.